Therefore, neoadjuvant therapy of mFOLFOX6 with bevacizumab and PD‐1 blockade may be a potential treatment strategy to better achieve tumor regression and increase R0 resection rates for pMMR/MSS locally advanced CRC patients. This evidence concerns the gene RPL17 and neoplasm.